Want to see TSE:CSCI full AI Analyst Report?
CSCI Stock Chart & Stats
C$7.50
-C$0.05(-0.65%)
At close: 4:00 PM EDT
C$7.50
-C$0.05(-0.65%)
Day’s Range― - ―
52-Week RangeC$3.30 - C$14.80
Previous CloseN/A
Volume1.00
Average Volume (3M)583.00
Market Cap
C$8.87M
Enterprise ValueC$1.56M
Total Cash (Recent Filing)C$5.27M
Total Debt (Recent Filing)C$1.95M
Price to Earnings (P/E)―
Beta2.68
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume313
30 Day Avg. Volume583
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Revenue And Gross MarginRevenue stabilization alongside a meaningful gross-margin improvement indicates the operating model is moving in a healthier direction. If maintained, better gross economics can increase the contribution from each sale and provide a stronger foundation for eventual profitability.
Narrowing Net LossesThe substantial reduction in annual losses shows progress toward improving earnings quality, even though the company remains unprofitable. Continued cost discipline and operating improvement could gradually reduce the funding burden and bring the business closer to sustainable earnings.
Conservative LeverageLow and improving leverage gives COSCIENS greater financial flexibility than a highly indebted balance sheet would provide. Reduced debt exposure limits interest and refinancing pressure, preserving more strategic room to support development while the company works toward profitability.
Bears Say
Persistent UnprofitabilityCOSCIENS remains deeply unprofitable despite narrowing losses, and the very negative net margin and ROE show that current operations are not yet generating adequate returns. This weak earnings base could continue to constrain internal investment and shareholder value creation.
Continued Cash BurnNegative operating and free cash flow indicate that the business continues to consume cash rather than fund itself. Although outflows improved from earlier periods, ongoing burn can increase reliance on external financing and limit the resources available for sustained product development.
Weak Top-Line Growth TrendThe broader revenue-growth measure remains negative, and the latest 3.5% TTM increase represents stabilization more than strong expansion. A limited growth trajectory can make it harder to absorb fixed costs, scale the platform, and convert margin improvements into durable profitability.
COSCIENS Biopharma News
CSCI FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was C$3.30 and its highest was C$14.80 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$8.87M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 23 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -C$0.267 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.267 in its last earnings report. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in TSE:CSCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―